United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ArcBest

AstraZeneca

Brighthouse Financial

Entravision Communications

HighPoint Resources

Moderna

Party City Holdco

Visa

Wayfair

December is likely to be filled with events or stock/sector specific news that could provide a boost to the stocks.

Stocks to Track in December as Markets Peak

APA Corporation

BioNTech SE

Chevron

Devon Energy

Diamondback Energy

TechnipFMC

Occidental Petroleum

The top five gainers of the S&P 500 in November were all energy firms - Occidental Petroleum (OXY), Devon Energy (DVN), Apache (APA), Diamondback Energy (FANG) and TechnipFMC (FTI).

Oil Ends Higher on Vaccine News Despite EIA's Bearish Report

Pfizer's stock is up just 3% since the start of the year and it has gained around 45% from its March lows. Despite the recent rally, Pfizer could offer an upside in the near term, as the company's revenues and earnings are expected to see strong gains going forward.

Here's Why Pfizer Stock Looks Inviting At $39 Levels

Consider the outlook for the rest of the company's units before investing.

Should Investors Buy Pfizer Stock for Its Coronavirus Vaccine?

Century Casinos

CVS Health

Johnson & Johnson

Kohl's

Altria

Wynn Resorts

There aren't many undervalued stocks out there, but some familiar, quality names fit the bill. We've pulled that list together for you.

7 Undervalued Stocks to Snap Up Today

The U.K. was the first country in the world to approve Pfizer and BioNTech's coronavirus vaccine for widespread use. In a way, that was the easy part.

'This is going to be challenging:' How the UK will roll out Pfizer's coronavirus vaccine

Intel

J. M. Smucker

As a dividend stock investor, for the first time, I feel a little uncertain of what the future may hold. We have three completely different industries here with Pharmaceutical/healthcare, Technology/IT and consumer-goods.

Dividend Stock Watch List: Lanny's December 2020 Edition

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.

Pfizer's Coronavirus Vaccine Gets a Nod in UK: ETFs to Shine

Snap

Spotify

Workhorse Group

Snap, Pfizer, Workhorse, Box and Spotify were our top stock trades for Thursday. With that in mind, let's have a look at the charts.

5 Top Stock Trades for Thursday: SNAP, PFE, WKHS, BOX, SPOT

European Union officials slammed the UK on Wednesday for rushing its landmark approval of Pfizer's coronavirus vaccine, saying health authorities shouldn't put speed ahead of safety. The British government cleared the COVID-19 shot early Wednesday, just 10 days after it started examining data from large-scale clinical trials run by Pfizer and its German partner, BioNTech.

European officials say UK rushed approval of Pfizer COVID-19 vaccine

The healthcare leaders became the first to receive emergency authorization for their coronavirus vaccine.

Why Pfizer and BioNTech Stocks Popped Today

The U.K. government granted emergency use authorization to the COVID-19 vaccine being developed by Pfizer Inc. and German partner BioNTech SE with some fanfare on Wednesday, but experts cautioned that the news does not mean the pandemic is close to being over.

What we still don't know about COVID vaccines after the U.K.'s emergency-use authorization of the Pfizer-BioNTech candidate

Blue-chip pharmaceutical giant Pfizer Inc. (NYSE:PFE) is making waves, as the company's coronavirus vaccine -- which was developed with BioNTech (BNTX) -- was granted emergency use approval in the U.K, after it was shown to be 95% effective in preventing COVID-19 infections.

Blue-Chip Pharmaceutical Stock Surges Following Vaccine Update

Pfizer Inc. (NYSE: PFE)-BioNTech SE – ADR (NASDAQ: BNTX) earned the distinction of being the first companies to receive regulatory authorization for emergency use of their investigational coronavirus vaccine candidate BNT162b2 following a positive verdict from the United Kingdom's drug regulator. Here's what investors should know about the combo's vaccine candidate:

What Pfizer, BioNTech Investors Need To Know About COVID-19 Vaccine With Conditional UK Approval

Merck

COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.

COVID-19 Vaccines Are on the Way and Major Players Are Cashing In

The drugmakers behind the COVID-19 vaccine approved Wednesday by United Kingdom authorities are studying whether it can be transported at higher temperatures than minus 94 degrees Fahrenheit (minus 70 Celsius), which would ease logistics challenges for getting people immunized, BioNTech CEO Ugar Sahin said.  In an interview on CNN shortly after the U.K. became the first Western nation to approve public use of the vaccine from U.S. pharmaceutical giant Pfizer (NYSE: PFE) and German partner BioNTech, Sahin said people in the U.K. could begin getting vaccinations by early next week.

Pfizer team evaluates higher shipping temperature for COVID vaccine

The vaccine will begin to be available to the public next week, says the government.

Pfizer and BioNTech's Coronavirus Vaccine Approved for Use in the U.K.

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate becomes the first-ever vaccine to get authorization.

Pfizer/BioNTech's COVID-19 Vaccine Gets Approval in U.K.

Encouraging News on COVID-19 Vaccine

Vaccine hopes are starting to be fulfilled as the first COVID-19 vaccine gets authorized.

Pfizer/BioNTech COVID-19 Vaccine Approved in the U.K.

Pfizer stock jumped early Wednesday after the pharmaceutical company's BioNTech-partnered coronavirus vaccine gained authorization in the U.K. Also, Merck sold its investment in Moderna. The post Pfizer Jumps After Nabbing First-Ever Coronavirus Vaccine Approval appeared first on Investor's Business Daily.

Pfizer Jumps After Nabbing First-Ever Coronavirus Vaccine Approval

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.

Pfizer/BioNTech Seek Marketing Nod for COVID-19 Vaccine in EU

Pfizer is seeking full marketing authorisation from Britain for its COVID-19 vaccine, an executive said on Wednesday as the U.S. drugmaker gears up to deliver by the weekend the first shots following approval for emergency use in the country.

Pfizer-BioNTech seeks full marketing approval from UK for COVID-19 vaccine

Moderna (MRNA), and Pfizer (PFE)/BioNTech (BNTX) file for emergency use authorization of their COVID-19 vaccine candidates in Europe

Will Americans Get COVID-19 Vaccine Sooner Than Europeans?

The UK became the first country in the world on Tuesday to grant emergency use authorization to Pfizer and BioNTech's COVID-19 vaccine. The vaccine, which demonstrated an efficacy rate of 95% in preventing COVID-19 among patients, will be made available to the country next week for a rollout to hospitals and vaccination centers across the country.

News for Pfizer Stock (PFE)